American society of clinical oncology expert statement: Collection and use of a cancer family history for oncology providers

Journal of Clinical Oncology

Volumn 32, Issue 8, 2014, Pages 833-840

  Lu, Karen H ^a   Wood, Marie E ^c   Daniels, Molly ^a   Burke, Cathy ^a   Ford, James ^d   Kauff, Noah D ^e   Kohlmann, Wendy ^f   Lindor, Noralane M ^g   Mulvey, Therese M ^h   Robinson, Linda ^b   Rubinstein, Wendy S ^k   Stoffel, Elena M ^l   Snyder, Carrie ^m   Syngal, Sapna ⁱ   Merrill, Janette K ⁿ   Wollins, Dana Swartzberg ⁿ   Hughes, Kevin S ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g MAYO CLINIC   (United States)

^h Southcoast Centers for Cancer Care   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k NATIONAL INSTITUTES OF HEALTH   (United States)

^l UNIVERSITY OF MICHIGAN   (United States)

^m CREIGHTON UNIVERSITY   (United States)

ⁿ AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACOUSTIC NEURINOMA; ADRENAL CORTEX CARCINOMA; ARTICLE; BREAST CANCER; CANCER FAMILY; CANCER RISK; CANCER SCREENING; CLINICAL PRACTICE; COLORECTAL CANCER; COWDEN SYNDROME; ENDOMETRIUM CANCER; EYE TUMOR; FAMILIAL CANCER; FAMILY HISTORY; GENETIC COUNSELING; GENETIC SCREENING; HEMANGIOBLASTOMA; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MELANOMA; ONCOLOGIST; ONCOLOGY; OPTIC PATHWAY TUMOR; OVARY CANCER; PANCREAS CANCER; PARAGANGLIOMA; PERITONEUM CANCER; PHEOCHROMOCYTOMA; PRIMARY TUMOR; PRIORITY JOURNAL; RETINOBLASTOMA; RHABDOID TUMOR; RISK ASSESSMENT; RISK MANAGEMENT; TERATOMA; THYROID MEDULLARY CARCINOMA; ANAMNESIS; GENETIC PREDISPOSITION; GENETICS; HEALTH CARE QUALITY; HEREDITY; NEOPLASM; PEDIGREE; PHENOTYPE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; STANDARD;

GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEREDITY; HUMANS; MEDICAL HISTORY TAKING; MEDICAL ONCOLOGY; NEOPLASMS; PEDIGREE; PHENOTYPE; PHYSICIAN'S PRACTICE PATTERNS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUALITY INDICATORS, HEALTH CARE; RISK ASSESSMENT; RISK FACTORS;

EID: 84899761198     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.9257     Document Type: Article

References (52)

1. Zon RT, Goss E, Vogel VG, et al: American Society of Clinical Oncology policy statement: The role of the oncologist in cancer prevention and risk assessment. J Clin Oncol 27:986-993, 2009
2. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol 14:1730-1736, 1996
3. American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. J Clin Oncol 21:2397-2406, 2003
4. Robson ME, Storm CD, Weitzel J, et al: American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. J Clin Oncol 28:893-901, 2010
5. Wilson BJ, Qureshi N, Santaguida P, et al: Systematic review: Family history in risk assessment for common diseases. Ann Intern Med 151:878-885, 2009
6. Rich EC, Burke W, Heaton CJ, et al: Reconsidering the family history in primary care. J Gen Intern Med 19:273-280, 2004 (Pubitemid 38388939)
7. Schneider KA, DiGianni LM, Patenaude AF, et al: Accuracy of cancer family histories: Comparison of two breast cancer syndromes. Genet Test 8:222-228, 2004 (Pubitemid 39586789)
8. Mitchell RJ, Brewster D, Campbell H, et al: Accuracy of reporting of family history of colorectal cancer. Gut 53:291-295, 2004 (Pubitemid 38125521)
9. Sijmons RH, Boonstra AE, Reefhuis J, et al: Accuracy of family history of cancer: Clinical genetic implications. Eur J Hum Genet 8:181-186, 2000 (Pubitemid 30189861)
10. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Genetic/familial high-risk assessment-Breast and ovarian. www.nccn.org/professionals/physician-gls/f-guidelines.asp
11. Lancaster JM, Powell CB, Kauff ND, et al: Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 107:159-162, 2007 (Pubitemid 47575743)
12. Lu K, Kauff N, Powell CB, et al: ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113:957-966, 2009
13. Lu K, Kauff N, Powell CB, et al: Hereditary breast and ovarian cancer syndrome. Gynecol Oncol 113:6-11, 2009
14. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Breast cancer screening and diagnosis. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp
15. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Colorectal cancer screening. www.nccn.org/professionals/physician- gls/f-guidelines.asp
16. Struewing JP, Abeliovich D, Peretz T, et al: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11:198-200, 1995; erratum 12:110, 1996
17. Rubinstein WS: Hereditary breast cancer in Jews. Fam Cancer 3:249-257, 2004
18. Zoigas A, Horick NK, Kinney AY, et al: Clinically relevant changes in family history of cancer over time. JAMA 306:172-178, 2011
19. Banks KC, Moline JJ, Marvin M, et al: 10 rare tumors that warrant a genetics referral. Fam Cancer 12:1-18, 2013
20. Hartman AR, Kaldate RR, Sailer LM, et al: Prevalence of BRCA mutations in an unselected population of triple-negative breast. Cancer 118:2787-2795, 2012
21. Schrader KA, Hurlburt J, Kalloger SE, et al: Germline BRCA1 and BRCA2 mutations in ovarian cancer: Utility of a histology-based referral strategy. Obstet Gynecol 120:235-240, 2012
22. Moreira L, Balaguer F, Lindor N, et al: Identification of Lynch syndrome among patients with colorectal cancer. JAMA 308:1555-1565, 2012
23. Giardiello FM, Brensinger JD, Petersen GM: AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 121:198-213, 2001 (Pubitemid 32591530)
24. Garg K, Leitao MM Jr, Kauff ND, et al: Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol 33:925-933, 2009
25. Raymond V, Else T, Everett JN, et al: Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab 98:E119-E125, 2013
26. Gozali AE, Britt B, Shane L, et al: Choroid plexus tumors: Management, outcome, and association with the Li-Fraumeni syndrome-The Children's Hospital Los Angeles (CHLA) experience, 1991-2010. Pediatr Blood Cancer 58:905-909, 2012
27. Galan SR, Kann PH: Genetics and molecular pathogenesis of phaeochromocytoma and paraganglioma. Clin Endocrinol (Oxf) 78:165-175, 2013
28. Plon SE, Nathanson K: Inherited susceptibility for pediatric cancer. Cancer J 11:255-267, 2005 (Pubitemid 44698793)
29. Machens A, Niccoli-Sire P, Hoegel J, et al: Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517-1525, 2003 (Pubitemid 37255037)
30. Richter S, Vandezande K, Chen N, et al: Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Hum Genet 72:253-269, 2003 (Pubitemid 36194237)
31. Foulkes WD, Bahubeshi A, Hamel N, et al: Extending the phenotypes associated with DICER1 mutations. Hum Mutat 32:1381-1384, 2011
32. Brosens LA, Langeveld D, van Hattem WA, et al: Juvenile polyposis syndrome. World J Gastroenterol 17:4839-4844, 2011
33. Kastrinos F, Steyerberg EW, Mercado R, et al: The PREMM1,2,6 model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 140:73-81, 2011
34. Chen S, Wang W, Lee S, et al: Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 296:1479-1487, 2006 (Pubitemid 44465512)
35. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20:2701-2712, 2002 (Pubitemid 34575644)
36. Wang W, Neindorf KB, Patel D, et al: Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. Cancer Res 70:552-559, 2010
37. Wang W, Chen S, Brune KA, et al: PancPRO: Risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 25:1417-1422, 2007 (Pubitemid 46706891)
38. Tinat J, Bougeard G, Baert-Desurmont S, et al: 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27:e108-e109, 2009
39. Tan MH, Mester J, Peterson C, et al: A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3,042 probands. Am J Hum Genet 88:42-56, 2011
40. Weissman SM, Burt R, Church J, et al: Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. J Genet Couns 21:484-493, 2012
41. Berg AO, Armstrong K, Botkin J, et al: Recommendations from EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11:35-41, 2009
42. Riley BD, Culver JO, Skrzynia C, et al: Essential elements of genetic cancer risk assessment, counseling, and testing: Updated recommendations of the National Society of Genetic Counselors. J Genet Counsel 21:151-161, 2012
43. Wood M, Stockdale A, Flynn BS: Interviews with primary care physicians regarding taking and interpreting the cancer family history. Fam Pract 25:334-340, 2008
44. Doerr M, Teng K: Family history: Still relevant in the genomics era. Cleve Clin J Med 79:331-336, 2012
45. Ozanne E, O'Connell A, Bouzan C, et al: Bias in the reporting of family history: Implications for care. J Genet Counsel 21:547-556, 2012
46. Lim JN, Hewison J: Do people really know what makes a family history of cancer? Health Expect [epub ahead of print on August 13, 2012]
47. US Department of Health and Human Services: Surgeon General's family health history initiative. www.hhs.gov/familyhistory
48. Feero WG, Bigley MB, Brinner KM, et al: New standards and enhanced utility for family health history information in the electronic health record: An update from the American Health Information Community's Family Health History Multi-Stakeholder Workgroup. J Am Med Inform Assoc 15:723-728, 2008
49. Rubinstein WS: Health risk assessment tools and family history, in Ginsburg GS, Willard HF (eds): Genomic and Personalized Medicine (ed 2). Oxford, United Kingdom, Academic Press, 2012, pp 306-323
50. Shabo A, Hughes KS: Family history information exchange services using HL7 clinical genomic standard specifications. Int J Semantic Web Inform Syst 1:42-65, 2005
51. Drohan B, Orzanne Em, Hughes KS: Electronic health records and the management of women at high risk of hereditary breast and ovarian cancer. Breast J 15:S46-S55, 2009 (suppl 1)
52. Sussner KM, Jandorf L, Valdimarsdottir HB: Educational needs about cancer family history and genetic counseling for cancer risk among frontline healthcare clinicians in New York City. Genet Med 13:785-793, 2011